Advertisement
News
Advertisement

Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes

Wed, 09/07/2011 - 6:33am
Bio-Medicine.Org

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16. Study results evaluating the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, as well as the investigational sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor, empagliflozin (BI-10773), will be featured among the seven presentations. Linagliptin 5 mg is marketed under the trade name Tradjenta™ (linagliptin) tablets in the U.S. and was approved by the U.S. Food and Drug Administration (FDA) in May 2011 to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

A long-term study evaluating the efficacy and safety of linagliptin in patients with type 2 diabetes was selected by EASD as an oral presentation, taking place on Friday, September 16.

The presentations are as follows: Linagliptin DataTitleFormat AuthorsDate/TimePreclinicalDPP-4 Inhibition - A New Approach for the Treatment of Uraemic Cardiomyopathy

Poster

824-P

L Chaykovska, K von Websky, S Heiden, J Rahnenfuhrer, T Klein, B Hocher

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (52-week)Long-term Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Severe Renal Impairment

Poster

821-P

J Newman, J McGill, S Patel, C Friedrich, C Sauce, H-J Woerle

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (pooled analysis)Linagliptin Improves

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading